Immune-related cutaneous adverse events associated with immune-checkpoint inhibitors: Our experience

Introduction: New “immune checkpoint inhibitors” (ICPI) are a group of monoclonal antibodies specifically created to activate cytotoxic T- cell response in order to fight against malignant cells. The activation of these pathways unbalance the immune system; there has been described numerous different immunologica l effects in multiple organs of the body. The aim of our study is to describe the cutaneous adverse events (CAE) related to the use of these drugs.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research